Medicines for Malaria Venture (MMV)

The Medicines for Malaria Venture (MMV) is a product development partnership in the field of antimalarial drug research and development. Its mission is to reduce the burden of malaria in disease-endemic countries by discovering, developing, and delivering new, effective, and affordable antimalarial drugs. In partnership with MMV, USAID support helped to move Coartem Dispersible – the first child-friendly artemisinin-based combination therapy for malaria – from product development to the scale-up stage. This important pediatric drug has since been introduced to 50 malaria-endemic countries worldwide, with more than 300 million pediatric treatments distributed. More recently, MMV supported the development of tafenoquine, a single dose cure for relapsing malaria. Tafenoquine was submitted for FDA approval in 2017 and is anticipated to be the first new drug in its class in 60 years. Support from USAID has also contributed to the progression of three novel classes of antimalarial drugs with the potential to be effective against drug-resistant strains of the parasite. These drugs may be promising alternatives to artemisinin-based formulations and are now being tested in patient trials. Read about USAID's new grant to MMV here.

Learn more at

Last updated: June 03, 2019

Share This Page